Abstract 2048
Background
Nuclear Autoantigenic Sperm Protein (NASP), a facilitator of chromatin assembly, is expressed as two splice variants: tNASP, specific for testis and cancer cells, and sNASP, expressed in all somatic cells. Exposure of tNASP to the immune system induces a robust humoral immune response. We suggested that patients with malignancies have a higher level of serum anti-tNASP antibodies than those without malignancies. We hypothesized that detection of anti-tNASP antibodies in serum can be used as a cancer screening test.
Methods
Sera from cancer patients and healthy individuals (negative control) were tested for the presence of antibodies against tNASP using enzyme-linked immunosorbent assay (ELISA) with a recombinant tNASP fragment as bait. A total of 139 serum samples from patients with a known malignancy were tested. These included bladder (11), brain (12), breast (12), endometrial (10), gastrointestinal (10), lung (10), ovarian (10), prostatic (12), skin (10), soft tissue (12), thyroid (10), or urinary (10) malignancy, as well as sera from 10 control patients with no known cancers (negative control).
Results
The majority of samples (56.5%) demonstrated elevated levels of anti-tNASP antibodies compared to negative control: glioblastoma, astrocytoma, colorectal adenocarcinoma, pulmonary adenocarcinoma, large-cell and squamous cell lung carcinoma, ovarian serous carcinoma, ovarian adenocarcinoma, bladder urothelial and squamous cell carcinoma, adenocarcinoma of the urinary bladder, prostate adenocarcinoma, and endometrial adenocarcinoma. Samples from patients with melanoma, renal, thyroid, breast carcinomas, and different types of sarcomas demonstrated similar levels of anti-tNASP antibodies as control samples.
Conclusions
Serum anti-tNASP antibody levels are markedly elevated in the majority of cancer patients tested as compared to healthy controls. These data demonstrate that detection of anti-tNASP antibodies is a viable diagnostic approach and has the potential to be used as an early noninvasive screening method for detection of multiple cancers.
Clinical trial identification
Legal entity responsible for the study
Oleg Alekseev.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract